Sarepta Therapeutics stock holds near USD 19.76 after analyst reset

Published on 09/19/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta Therapeutics stock traded at USD 19.76 on September 18, 2026. MarketBeat shows a consensus Hold rating and an average target of USD 25.69.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics stock (ISIN US8036071004) traded at USD 19.76 on September 18, 2026, with a market capitalization of USD 2.12 billion and a 52-week range of USD 14.68 to USD 25.32. MarketBeat shows a consensus Hold rating and an average 12-month target of USD 25.69, about 30.0 percent above the latest close.

Analysts still see upside

According to MarketBeat on September 19, 2026, the average target for Sarepta Therapeutics is USD 25.69, with 9 buy ratings, 5 hold ratings and 6 sell ratings in coverage. The same overview puts the upside at 30.0 percent from USD 19.76.

Latest numbers on record

MarketBeat also summarizes the company's latest reported quarter as Q2 2026, with revenue of USD 611.8 million and EPS of minus USD 2.22. That compares with revenue of USD 362.1 million in the prior-year period, a gain of 68.9 percent.

For investors, the gap between the USD 19.76 share price and the USD 25.69 consensus target matters more than the headline rating. The current market value of USD 2.12 billion leaves the stock well inside its 52-week band.

Stock stays below target

Sarepta Therapeutics stock closed at USD 19.76 on September 18, 2026, after trading in a 52-week range from USD 14.68 to USD 25.32. The quote sits 21.9 percent below the high and 34.6 percent above the low.